Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,947 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronavirus Disease 2019 (COVID-19) Pneumonia Clear all
Completed No phase listed Observational

Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset

NCT04729075
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
ARDS and COVID19 treatments
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Not listed No phase listed Observational

The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey

NCT05312619
View directory record Official record
Conditions
COVID-19, Lyme Disease, COVID-19 Vaccine
Interventions
Cross sectional survey
Other
Lead sponsor
Dr. Daniel Cameron & Associates
Other
Eligibility
12 Years and older
Enrollment
2,000 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Mount Kisco, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 9, 2026, 8:52 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19

NCT04358211
View directory record Official record
Conditions
COVID-19
Interventions
Biological: COVID-19 convalescent plasma
Biological
Lead sponsor
Nakhle Saba, MD
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

New Reusable Mask Design With Superior Filtration and Fit

NCT04826809
View directory record Official record
Conditions
Covid19, Tuberculosis, Respiratory Viral Infection
Interventions
N95 mask, Nordell single E-100 layer mask, Nordell double E-100 layer mask
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Mankato, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Completed No phase listed Observational

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

NCT05256316
View directory record Official record
Conditions
COVID-19
Interventions
Previously admitted COVID-19 patients in intensive care units
Other
Lead sponsor
The University of Queensland
Other
Eligibility
18 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

NCT05137236
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • Hollywood, Florida • Sunrise, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 9, 2026, 8:52 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

NCT04708236
View directory record Official record
Conditions
COVID-19
Interventions
ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose, Vehicle control
Drug · Other
Lead sponsor
Oryn Therapeutics, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Patients With COVID-19

NCT04385199
View directory record Official record
Conditions
Coronavirus Infection, Coronavirus, COVID
Interventions
Convalescent plasma
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

NCT04625972
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
50
States / cities
Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

NCT05736874
View directory record Official record
Conditions
Covid19
Interventions
Fluticasone, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

NCT04575597
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
Peoria, Arizona • Los Angeles, California • North Hollywood, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Withdrawn Phase 1 Interventional

Sirolimus in COVID-19 Phase 1

NCT04371640
View directory record Official record
Conditions
SARS-CoV-2, Covid-19
Interventions
Sirolimus 1 MG/ML, Placebo
Drug
Lead sponsor
Walter K. Kraft
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 9, 2026, 8:52 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 9, 2026, 8:52 AM EDT
Completed No phase listed Observational

CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases

NCT06907953
View directory record Official record
Conditions
Pancreatitis, Chronic, Sarcoidosis, VCP Disease, Long COVID, PCD, Symptoms and Signs, Wearables
Interventions
Observational - no intervention
Other
Lead sponsor
4YouandMe
Other
Eligibility
14 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 9, 2026, 8:52 AM EDT
Not listed No phase listed Observational

Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function

NCT04506229
View directory record Official record
Conditions
Covid19
Interventions
Whole exome sequencing
Genetic
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)

NCT05178173
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, SARS CoV 2 Infection
Interventions
Placebo Comparator: Sterile Water, 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 9, 2026, 8:52 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

NCT04828161
View directory record Official record
Conditions
COVID-19
Interventions
ensovibep, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
27
States / cities
Jasper, Alabama • Colton, California • Fullerton, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 9, 2026, 8:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advance Care Planning: Communicating With Outpatients for Vital Informed Decision

NCT04660422
View directory record Official record
Conditions
Advanced Care Planning, Shared Decision Making, Video Decision Aids, Communication Skills, Advance Directives, Natural Language Processing, Covid19
Interventions
VitalTalk communication skills training, ACP Decisions Video Program, Intervention training:, Medical Record Review
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
42,019 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

NCT04813796
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Messaging for Vaccination

NCT05182554
View directory record Official record
Conditions
Vaccination Refusal, COVID-19 Pandemic
Interventions
Doctor Videos, Sharing Videos, Sharing Videos (Influencers), Vaccine Ambassador, Video framing, Video order
Behavioral
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 9, 2026, 8:52 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans

NCT04805931
View directory record Official record
Conditions
Covid19, Vaccine Refusal
Interventions
Behavioral economics
Behavioral
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
18 Years and older
Enrollment
4,311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 9, 2026, 8:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

NCT04347954
View directory record Official record
Conditions
COVID-19
Interventions
Povidone-Iodine 2%, Povidone-Iodine 0.5%, Isotonic saline 0.9%
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 9, 2026, 8:52 AM EDT
Terminated No phase listed Observational

Cardiovascular Implications of COVID-19

NCT04435457
View directory record Official record
Conditions
SARS-CoV 2, SARS Pneumonia, COVID-19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Cardiac Complication
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 9, 2026, 8:52 AM EDT